# CellSight Technologies

Source: https://onco.cc/companies/cellsight-technologies/  
OnCo record `cellsight-technologies` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

CellSight Technologies is a US-based imaging company that leads 2 cancer trials in OnCo, testing the activated T-cell PET tracer [18F]F-AraG (VisAcT) in non-small-cell lung cancer.

## Summary

CellSight Technologies develops molecular imaging agents that originated in Sanjiv Gambhir's laboratory at Stanford University. Its lead agent VisAcT ([18F]F-AraG) is a PET tracer that accumulates in activated T cells, intended to help select patients for immunotherapy, assess early response and detect immune-related side effects. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT06107374 (phase 2, Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG) and NCT06084806 (phase 2, Test-retest Evaluation of [18F]F-AraG PET). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-17
- Also known as: CellSight Technologies, Inc.
- Tags: ctgov-sponsor
- HQ: San Francisco, California
- Type: imaging
- Website: https://www.cellsighttech.com

## Sources

- Official website: https://www.cellsighttech.com
- ClinicalTrials.gov: trials led by CellSight Technologies: https://clinicaltrials.gov/search?lead=CellSight%20Technologies%2C%20Inc.

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- trials: [Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG](https://onco.cc/trials/nct06107374/), [Test-retest Evaluation of [18F]F-AraG PET](https://onco.cc/trials/nct06084806/)

---
JSON: https://onco.cc/api/v1/entities/cellsight-technologies.json